CW May 2006
Volume 15Issue Number 5 May 2006 ISSN 10593802 GIST Mutation Responds Better to Higher Dose ImatinibAnalysis of a study among patients with advanced gastrointestinal stromal tumors (GISTs) has led researchers to conclude that higher doses of imatinib are warranted for some patients, and that molecular subclassification of GISTs is warranted for all.
Go to Previous Page Go to Next Page Source & Additional Reading M. Heinrich, European Journal of Cancer, Volume 42, Issue 8, May 2006, Pages 1093-1103. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW May 2006Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
